Literature DB >> 4073094

Pharmacology of ticarcillin combined with clavulanic acid in humans.

B E Scully, N X Chin, H C Neu.   

Abstract

Serum and urine levels of ticarcillin and clavulanic acid after administration of doses of 50 mg/kg and 1.7 mg/kg or 50 mg/kg and 3 g/0.1 g, respectively, are potentially toxic to susceptible bacteria. Both compounds are widely distributed in body tissues and fluids, with concentrations exceeding the minimal inhibitory concentrations of most pathogens. Excretion is primarily renal, although there is some metabolism of clavulanate in the body. Due to accumulation, dosage adjustment is required for patients with renal insufficiency. Both ticarcillin and clavulanic acid are cleared by hemodialysis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4073094     DOI: 10.1016/0002-9343(85)90127-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  7 in total

1.  Ticarcillin-clavulanic acid dosing ratio for treatment of experimental Staphylococcus aureus endocarditis.

Authors:  J S Goodman
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

2.  Effect of clavulanic acid on the activity of ticarcillin against Pseudomonas aeruginosa.

Authors:  F Tausk; C W Stratton
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

3.  Comparative efficacies of ticarcillin, ticarcillin/clavulanic acid, piperacillin and cefoxitin against polymicrobial infections in mice caused by Escherichia coli and Bacteroides fragilis.

Authors:  A S Beale; J Gisby
Journal:  Infection       Date:  1991 Mar-Apr       Impact factor: 3.553

4.  Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations.

Authors:  M B Marques; E S Brookings; S A Moser; P B Sonke; K B Waites
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

6.  Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.

Authors:  M R Jacobs; S C Aronoff; S Johenning; D M Shlaes; S Yamabe
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

7.  Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin.

Authors:  P D Lister; V M Gardner; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.